Recurrent Glioblastoma Clinical Trials

41 recruiting

Recurrent Glioblastoma Trials at a Glance

47 actively recruiting trials for recurrent glioblastoma are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 1 with 24 trials, with the heaviest enrollment activity in Boston, San Francisco, and New York. Lead sponsors running recurrent glioblastoma studies include National Cancer Institute (NCI), Mayo Clinic, and Jonsson Comprehensive Cancer Center.

Browse recurrent glioblastoma trials by phase

Treatments under study

About Recurrent Glioblastoma Clinical Trials

Looking for clinical trials for Recurrent Glioblastoma? There are currently 41 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Recurrent Glioblastoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Recurrent Glioblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 47 trials

Recruiting
Phase 1

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
Northwestern University30 enrolled1 locationNCT06410248
Recruiting
Phase 2

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Recurrent Glioblastoma
BioNTech SE75 enrolled6 locationsNCT07297212
Recruiting
Phase 1

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Glioblastoma MultiformeRecurrent Glioblastoma
Boston Scientific Corporation36 enrolled9 locationsNCT05303467
Recruiting
Phase 1

Sonodynamic Therapy in Patients With Recurrent GBM

GBMGlioblastoma MultiformeRecurrent Glioblastoma
Shayan Moosa, MD11 enrolled1 locationNCT06039709
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 3

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

GlioblastomaGBMRecurrent Glioblastoma
CarThera560 enrolled48 locationsNCT05902169
Recruiting
Phase 1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

GlioblastomaMalignant GliomaRecurrent Glioblastoma+2 more
Beijing Biotech36 enrolled1 locationNCT07551336
Recruiting
Phase 2

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

Recurrent Glioblastoma
Duke University80 enrolled4 locationsNCT06069726
Recruiting
Early Phase 1

Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma

Recurrent Glioblastoma
Huashan Hospital10 enrolled1 locationNCT07538128
Recruiting
Phase 2

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Recurrent GlioblastomaProgressive Glioblastoma
National Cancer Institute (NCI)184 enrolled324 locationsNCT06325683
Recruiting
Phase 1

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

GliomaRecurrent GlioblastomaAstrocytoma
National Cancer Institute (NCI)28 enrolled1 locationNCT06344130
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 1

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Resectable GlioblastomaIDH Wildtype GlioblastomaRecurrent Astrocytoma+2 more
Jonsson Comprehensive Cancer Center10 enrolled1 locationNCT07089641
Recruiting
Phase 1

Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-WildtypeAstrocytoma, Grade IV
Mayo Clinic20 enrolled1 locationNCT05789394
Recruiting
Not Applicable

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent Gliomas
Alpha Tau Medical LTD.10 enrolled1 locationNCT06910306
Recruiting
Phase 2

Sacituzumab Govitecan in Recurrent Glioblastoma

Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio32 enrolled3 locationsNCT04559230
Recruiting
Phase 1

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

GlioblastomaEGFR Gene MutationMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD20 enrolled1 locationNCT06186401
Recruiting
Phase 1

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Recurrent GlioblastomaRecurrent Malignant GliomaRecurrent Gliosarcoma+2 more
M.D. Anderson Cancer Center36 enrolled1 locationNCT03896568
Recruiting
Phase 1

CUE-102 in Recurrent Glioblastoma

GlioblastomaGlioma, MalignantRecurrent Glioblastoma
David Reardon, MD18 enrolled2 locationsNCT06917885
Recruiting
Phase 2

Surgical Pembro +/- Olaparib w TMZ for rGBM

GlioblastomaRecurrent Glioblastoma
L. Nicolas Gonzalez Castro, MD, PhD78 enrolled4 locationsNCT05463848